LivaNova (NASDAQ:LIVN) Price Target Increased to $66.00 by Analysts at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its price target raised by Robert W. Baird from $58.00 to $66.00 in a report published on Thursday, Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other analysts have also commented on the company. Mizuho boosted their price target on LivaNova from $75.00 to $80.00 and gave the company a buy rating in a research note on Thursday. Needham & Company LLC reiterated a buy rating and issued a $72.00 price target on shares of LivaNova in a research report on Wednesday. StockNews.com upgraded LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Finally, Barclays lifted their price target on LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research note on Monday, February 26th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $66.20.

LivaNova Trading Up 2.0 %

Shares of NASDAQ:LIVN traded up $1.23 during mid-day trading on Thursday, hitting $64.15. The stock had a trading volume of 891,504 shares, compared to its average volume of 781,875. The company’s 50 day moving average is $54.57 and its 200-day moving average is $50.94. The company has a market cap of $3.47 billion, a PE ratio of -106.92 and a beta of 0.92. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.51 and a current ratio of 3.17.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The firm had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. During the same quarter last year, the firm earned $0.43 earnings per share. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, sell-side analysts predict that LivaNova will post 3.01 EPS for the current year.

Institutional Trading of LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. Headlands Technologies LLC purchased a new stake in LivaNova during the third quarter valued at about $72,000. Picton Mahoney Asset Management purchased a new position in shares of LivaNova in the 3rd quarter worth about $91,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of LivaNova during the third quarter valued at approximately $217,000. AlphaMark Advisors LLC bought a new stake in shares of LivaNova in the 3rd quarter worth $244,000. Finally, Jump Financial LLC purchased a new position in LivaNova in the 3rd quarter worth about $273,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.